Abstract:Factor XIa, as a blood coagulation enzyme, amplifies the generation of the last enzyme thrombin in the blood coagulation cascade. It was proved that direct inhibition of factor XIa could reduce pathologic thrombus formation without an enhanced risk of bleeding. WSJ-557, a nonpurine imidazole-based xanthine oxidase inhibitor in our previous reports, could delay blood coagulation during its animal experiments, which prompted us to investigate its action mechanism. Subsequently, during the exploration of the action mechanism, it was found that WSJ-557 exhibited weak in vitro factor XIa binding affinity. Under the guide of molecular modeling, we adopted molecular hybridization strategy to develop novel factor XIa inhibitors with WSJ-557 as an initial compound. This led to the identification of the most potent compound 44g with a Ki value of 0.009 μM, which was close to that of BMS-724296 (Ki = 0.0015 μM). Additionally, serine protease selectivity study indicated that compound 44g display a desired selectivity, more 400-fold than those of thrombin, factor VIIa and factor Xa in coagulation cascade. Moreover, enzyme kinetics studies suggested that the representative compound 44g acted as a competitive-type inhibitor for FXIa, and molecular modeling revealed that it could tightly bind to the S1, S1′ and S2′ pockets of factor XIa. Furthermore, in vivo efficacy in the rabbit arteriovenous shunt model suggested that compound 44g demonstrated dose-dependent antithrombotic efficacy. Therefore, these results supported that compound 44g could be a potential and efficacious agent for the treatment of thrombotic diseases.

Synthesis and Factor Xa Inhibitory Activity of Apixaban Derivatives

Synthesis and evaluation of oxazolidinone ether compounds as factor Xa inhibitors

Synthesis of 3,4-Diaminobenzoyl Derivatives As Factor Xa Inhibitors

Synthesis, Crystal Structures, Fluorescence and Xanthine Oxidase Inhibitory Activity of Pyrazole-Based 1,3,4-Oxadiazole Derivatives

Synthesis and Factor Xa Inhibitory Activity of Rivaroxaban Derivatives

Design, Synthesis and Evaluation of Isoxazolo[5,4-D]Pyrimidin-4(5h)-One Derivatives As Antithrombotic Agents

Study on the synthesis of apixaban

Synthesis and Evaluation of Anthranilamide-Based Derivatives As FXa Inhibitors.

Design and synthesis of novel factor XIa Inhibitors with bicyclic isoquinoline and naphthalene fragments

Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.

Design, Synthesis and Biological Evaluation of Anthranilamide Derivatives As Potential Factor Xa (fxa) Inhibitors

Alternate Synthesis of Apixaban (BMS-562247), an Inhibitor of Blood Coagulation Factor Xa

Novel Anthranilamide-Based Fxa Inhibitors: Drug Design, Synthesis And Biological Evaluation

Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa

Design and prediction of new anticoagulants as a selective Factor IXa inhibitor via three-dimensional quantitative structure-property relationships of amidinobenzothiophene derivatives.

Design, Synthesis and Antithrombotic Evaluation of Novel Non-Peptide Thrombin Inhibitors.

Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment

Synthesis and Antithrombotic Activity of 3-Aryl-1,2,3,4-oxatriazole-5-imine-coupled Aspirin

Amino(methyl) Pyrrolidines As Novel Scaffolds for Factor Xa Inhibitors

Design, Synthesis, and Thrombin Inhibitory Activity Evaluation of Some Novel Benzimidazole Derivatives

Synthesis of 5-amido-1H-imidazo[5,4-b]pyridine derivatives and their angiotensin II receptor antagonistic activities